Self-prescribing TRT: separating real risks from gym-bro mythology

What did @alphaclubsupps actually say?

Chris, a self-described "TRT and Men's Health Advocate," laid out three mistakes he says men make when starting testosterone replacement therapy on their own. First, dosing too high, what he calls starting on a "Billy Big Bollocks dose." Second, expecting TRT to fix everything without addressing sleep, diet, and training. Third, skipping bloodwork entirely, which he frames as the single most important non-negotiable. He also flipped the order in his verbal delivery versus his caption, putting bloodwork last rather than first, and calling it the most fundamental step of the three.

He's not a clinician. He doesn't cite any studies. But the three points he raises are real concerns that show up repeatedly in the clinical literature on testosterone misuse and self-administration. The question is whether he framed them accurately or oversimplified in ways that could mislead people.

Does the science back this up?

On the dosing point, yes, broadly. The evidence on supraphysiologic testosterone and cardiovascular, hematologic, and endocrine harm is substantial and well-documented. On lifestyle, the claim is directionally correct but more complicated than he suggests. On bloodwork, he's right, and the data on unmonitored testosterone use is genuinely alarming.

A 2019 review by Mulhall et al. in the Journal of Urology on testosterone deficiency guidelines makes clear that baseline and follow-up bloodwork, including total testosterone, hematocrit, PSA, and lipids, is standard of care before and during any TRT protocol. Men who self-administer without this monitoring have no way of knowing whether their hematocrit is climbing toward stroke-risk territory or whether their lipid panel has shifted. A 2022 analysis by Bhatta et al. in the Journal of the Endocrine Society found that a meaningful proportion of men obtaining testosterone through non-traditional channels had never had a confirmed hypogonadism diagnosis, which is exactly the population Chris is describing.

On lifestyle, the picture is more nuanced. Research by Saad et al. (2016, Andrology) showed that testosterone therapy combined with lifestyle intervention produced better metabolic outcomes than either alone. Chris is right that TRT is not a standalone fix, but framing it as "grease the wheels" is a reasonable lay summary of the interaction effect.

What did they get wrong (or right)?

He got the substance mostly right, but there are gaps worth naming. He gets real credit for telling his audience that bloodwork is non-negotiable and that running high doses is not the same as replacement. That distinction matters. A lot of content in this space quietly conflates cycle-level dosing with TRT, and he calls it out directly.

What he got wrong, or at least incomplete, is the order of operations. He says "I would have assumed you would have had your blood work done before you even started," but frames this as his third point, almost an afterthought. Clinically, confirmed hypogonadism via bloodwork is the first requirement, not a bonus step. The Endocrine Society's 2018 clinical practice guidelines (Bhasin et al., Journal of Clinical Endocrinology and Metabolism) are unambiguous: TRT should only be initiated in men with symptomatic hypogonadism confirmed by two fasting morning testosterone measurements. If you haven't confirmed deficiency, you have no business starting.

He also never mentions the risk of suppressing endogenous testosterone production, fertility effects, or the need for a licensed prescriber. These aren't minor omissions when you're talking to an audience that may be self-prescribing. Mentioning "sides" without specifying what they are, polycythemia, elevated hematocrit, cardiovascular strain, leaves viewers with a vague warning rather than actionable information.

What should you actually know?

If you're considering TRT, the starting point is not a dose or a protocol. It's a diagnosis. Two separate fasting morning blood draws showing total testosterone below the lab's reference range, combined with symptoms, is the clinical threshold most guidelines use. One test is not enough. Symptoms alone are not enough. And "feeling low" without a confirmed diagnosis is not an indication for testosterone therapy.

Supraphysiologic dosing, the "Billy Big Bollocks" doses Chris mentions, carries documented risks. Polycythemia (elevated red blood cell count) is one of the most common, and it raises the risk of clotting events including deep vein thrombosis and stroke. A 2023 meta-analysis by Wallis et al. in JAMA Network Open found that testosterone use was associated with increased cardiovascular events in some populations, particularly older men with pre-existing risk factors. That doesn't mean TRT is inherently dangerous when properly managed, but it does mean monitoring matters.

If you're working with a regulated telehealth provider, expect bloodwork before initiation, follow-up labs at 3 and 6 months, and ongoing monitoring. If a service offers testosterone without any of that, that is a red flag, not a convenience.